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We evaluated quality of life (QL) and quality-adjusted survival in International Breast Cancer Study Group Trial IX, a randomised trial
including 1669 eligible patients receiving tamoxifen for 5 years or three prior cycles of cyclophosphamide, methotrexate and 5-
fluorouracil (CMF) followed by 57 months tamoxifen. During the time with CMF toxicity (Tox), without symptoms and toxicity
(TWiST), and following relapse (Rel), patients scored their QL indicators and a utility indicator for subjective health estimation
between ‘perfect’ and ‘worst’ health. Scores were averaged within Tox, TWiST and Rel and transformed to utilities. Mean durations
for the three transition times were weighted with utilities to obtain mean quality-adjusted TWiST (Q-TWiST). Patients receiving CMF
reported significantly worse scores for most QL domains at month 3, but less hot flushes. After completing chemotherapy, there
were no differences by treatment groups. Benefits evaluated by Q-TWiST favoured the additional chemotherapy. CMF provided 3
more months of Q-TWiST for patients with ER-negative tumours, but CMF provided no benefit in Q-TWiST for patients with ER-
positive tumours. Q-TWiST analysis based on patient ratings is feasible in large-scale cross-cultural clinical trials.
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The International Breast Cancer Study Group (IBCSG) recently
presented first results of a randomised trial (Trial IX) testing the
role of adjuvant chemotherapy preceding treatment with tamox-
ifen for postmenopausal patients with lymph node-negative breast
cancer (International Breast Cancer Study Group, 2002). Patients
showed substantially better disease-free survival (DFS) with
adjuvant chemotherapy if their oestrogen receptor (ER) status
was negative (i.e. endocrine nonresponsive). In contrast, if their
cancer was ER-positive (i.e. endocrine-responsive), they obtained
no benefit from the chemotherapy compared with tamoxifen alone.
In this report, we extend the analysis to quantify trade-offs based
on quality of life (QL) and quality-adjusted survival (QAS).
The objective of the QL analysis was an extension of our earlier
findings on the impact of adjuvant therapy on QL (Hu ¨rny et al,
1996b). Presence, duration, timing and anticipation of chemother-
apy had a measurable effect on patients’ QL, but patients’
psychological adaptation was found to be more important for
their QL than cytotoxic side effects. In this trial, we used additional
QL indicators (Bernhard et al, 1997).
The objective of the QAS analysis was an extension of the
Q-TWiST model designed to evaluate ‘trade-offs’ in clinical trials
(Goldhirsch et al, 1989). This model divides the life-span from the
beginning of adjuvant treatment until death into three time
segments corresponding to distinct health states: Tox (time with
toxicity), TWiST (time without symptoms and toxicity) and Rel
(time after systemic relapse). In previous trials, Tox and Rel were
weighted by arbitrary utilities and added to TWiST to reach an
overall assessment of different treatment groups. In this trial,
patients were asked to directly assess the relevant utilities during
Tox, TWiST and Rel using a scale which asked them to imagine
that they would have to live the rest of their life in their current
condition and then to rate this condition between ‘perfect health’
and ‘worst health’. This scale has been shown to correspond to
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et al, 1998).
QL and QAS are usually evaluated separately despite their
complementary objectives: understanding the pattern of morbidity
and adaptation (QL), and providing information for clinical policy
and decision-making (QAS). In this analysis, we link these two
concepts to provide a quantitative backing for the trade-offs
inherent in the use of effective but toxic therapies.
PATIENTS AND METHODS
The Trial
Between October 1988 and August 1999, 1715 postmenopausal
patients were randomly assigned to receive either tamoxifen
(20mgday
 1) for 60 months or three 28-day courses of CMF
(cyclophosphamide at 100mgm
 2 orally on days 1–14, metho-
trexate at 40mgm
 2 intravenously on days 1 and 8 and 5-
fluorouracil at 600mgm
 2 intravenously on days 1 and 8, followed
by tamoxifen (20mgday
 1) for 57 months. Tamoxifen following
chemotherapy was to begin on day 15 of the final course of CMF.
Of the 1715 patients randomly assigned, 1669 (97%) were eligible
and assessable. The details of the trial protocol and conduct are
described elsewhere (International Breast Cancer Study Group,
2002). The median follow-up of this analysis was 71 months.
Participating investigators are displayed in Appendix A.
Patients were asked to complete a QL form at beginning of
treatment (baseline), 2 months later (i.e. day 1 of cycle 3 or 8 weeks
after tamoxifen start), at each 3 months for the first year, at
months 18 and 24, and 1 and 6 months after relapse. This schedule
was expanded, with yearly assessments up to month 72 (June 1995)
regardless of the disease status (December 1996), that is, the 1 and
6 month assessments following relapse were dropped.
Quality of life analysis
We predicted worse QL during chemotherapy (month 3) but no
residual effects among treatment groups after completion of
chemotherapy (Hu ¨rny et al, 1996b). A clinically meaningful
difference was defined based on our previous observations of the
coping indicator in postmenopausal patients with lymph node-
positive breast cancer (Hu ¨rny et al, 1996b), as the ratio of the
average change between baseline and month 3 in patients with
Tam alone vs those with three initial cycles CMF followed by Tam
(ratio¼3.37; not shown in the original article). We chose to use
the ratio instead of the absolute difference in scores because the
baseline scores in the present trial were better than those of the
earlier trial, which involved women with node-positive disease.
As a secondary hypothesis, we expected smaller adverse effect of
CMF on QL at month 3 for patients with ER-negative than those
with ER-positive tumours. We reasoned that patients with ER-
negative tumours would be more likely to feel that chemotherapy
was necessary and therefore find it more bearable than patients
with ER-positive disease.
We report QL data for the first 24 months in patients without
recurrence within this time. Of the 1669 eligible and assessable
patients, 1398 patients were included in the QL analysis. Of these,
803 completed all of their assessments using the 1993 version of
the IBCSG QL Core Form (Bernhard et al, 1997). This form
comprised indicators for physical well being, mood (Hu ¨rny et al,
1996a), coping effort (Hu ¨rny et al, 1993), appetite, tiredness, hot
flushes, nausea/vomiting, perceived social support, restrictions in
arm movement and subjective health estimation (SHE) (Hu ¨rny
et al, 1998) in the linear analogue self-assessment (LASA) format.
The other 595 patients either filled out all of their assessments
using the previous version of the form, which included four of
these indicators (physical well being, mood, coping effort,
appetite) (Butow et al, 1991), or they filled out a combination of
the two. For consistency, only data provided by the 803 patients
mentioned above were used for the analyses of the additional
indicators. All indicators were analysed separately.
To test for differences between treatments in QL scores at each
time point, we used ANOVA adjusting for culture (country/
language; see Table 1 for definitions). For baseline analysis and
tests for heterogeneity among treatment groups at each time point,
we used the square roots of the scores (Hu ¨rny et al, 1996b) because
this transformation approximated a normal distribution and was
effective in stabilising the variances for all indicators. The figures
however show the results in the original scores from 0 to 100.
We also tested for differences in QL scores between baseline and
month 3 and 6, respectively, of the within-patient changes in an
ANOVA model that included assigned treatment and culture. The
intrapatient differences were normally distributed for all QL
scores.
Quality-adjusted survival analysis
For this analysis, we used the SHE indicator as designed for QAS
(Hu ¨rny et al, 1998). Patients were asked to imagine that they would
have to live the rest of their life in their current condition and then
to rate this condition between ‘perfect health’ and ‘worst health’.
This indicator was previously validated against a time trade-off
(TTO) interview (i.e. a preference measure) in patients with
metastatic breast cancer. The conventional negative anchor ‘death’
was replaced by ‘worst health’ in the adjuvant setting since the two
versions showed comparable results and ‘death’ was judged to be
an unacceptable anchor for some of the language/culture groups in
the present study.
Following the Q-TWiST model (Goldhirsch et al, 1989), we
defined three clinical health states: Tox, TWiST and Rel. The
clinical question of this trial was the impact of adding three cycles
of CMF. Therefore, Tox was calculated only in patients randomised
to receive CMF.
To calculate Q-TWiST, each health state is assigned a utility
coefficient (ut, utwist and urel) which gives a value to time spent in
the state relative to the value of an equal amount of time spent in a
state of ‘perfect health’. The utilities are assumed to be in the
interval [0,1], where a zero indicates worst possible health, and
unity indicates a state as good as perfect health. The Q-TWiST
model is obtained by taking the linear combination of the health
state durations adjusted by the respective utilities:
Thus;Q   TWiST ¼ ut Tox þ utwist TWiST þ ur Rel
Table 1 Description of patients excluded from the quality of life (QL)
analysis
Total eligible cases 1669
Exclusions from analysis
Relapse within first 24 months of randomisation 136
Completed no QL forms 98
Completed QL forms in multiple languages 33
Undefined culture
a 4
Assessable cases 1398
b
aCulture is defined by the following language/country combinations: English/Australia;
New Zealand; English/South Africa; French/Switzerland; German/Switzerland; Italian/
Switzerland; Italian/Italy; Slovenian/Slovenia; Spanish/Spain; Swedish/Sweden.
bOf the
1398 patients, 803 completed all of their assessments using the 1993 version of the
QL form. These 803 patients were used for the analyses of indicators included alone
on this version of the form (tiredness, hot flushes, nausea/vomiting, social support,
arm movement and SHE). All 1398 patients were used for the analyses of indicators
included on both versions of the QL form (physical well being, mood, appetite and
PACIS).
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the utilities to evaluate Q-TWiST. We hypothesised that utilities
derived from observed SHE values in both the Tox and Rel states
would be substantially higher than the arbitrary value of 0.5 used
to illustrate the Q-TWiST method when it was introduced
(Goldhirsch et al, 1989). Also, we predicted that the actual scores
during the TWiST state would be less than ‘perfect’, if only because
all patients were receiving Tam.
Within each defined health state, all available SHE scores were
used (N¼1669). For Tox, we used the median value at month 3
(i.e. peak of toxicity). For TWiST, we used the median of the SHE
scores averaged within patients over the first 24 months after
randomisation (excluding the first 3 months in patients with
CMF). For Rel, we used the median of the SHE scores averaged
within patients over the first 6 months after relapse. These SHE
estimates were converted to quality weights using a power
transformation: TTO¼1–(1–SHE)
a (Torrance et al, 1996; Tor-
rance et al, 2001). We used the a value from our validation study
(a¼1.6) and performed a sensitivity analysis for a range of
published a’s.
An exploratory analysis was conducted to assess ut confined to
those patients who had any recorded subjective toxic effect of
grade 2 or higher (excluding amenorrhea) during their chemother-
apy as was done in the original Q-TWiST model (Goldhirsch et al,
1989).
Mean health state durations were estimated from censored
survival data (product limit method) up to 72 months from
randomisation by computing the areas between the survival curve
estimates for the transition times. These durations were adjusted
using the patient-derived utilities in order to estimate mean
Q-TWiST for each treatment group. The treatments were separately
compared overall and within the prospectively stratified ER-
negative and ER-positive cohorts.
We performed a threshold utility analysis both overall and
within the ER-negative and ER-positive cohorts. These findings
provide a decision aid for a range of utilities for Tox and Rel. To
account for the less than ‘perfect health’, we divided each of the
three utilities by the patient estimated utwist so that Q-TWiST is
interpreted relative to TWiST and more accurately reflects the
patients’ perception during the time period: Q-TWiST¼
ut/utwist Toxþutwist/utwist TWiST ur/utwist Rel. The treatment
comparison results are presented for all possible values of the
utilities.
For all analyses, P-values less than 0.05 were deemed statistically
significant. No adjustment was made for multiple testing.
RESULTS
Quality of life
Of the 1669 eligible patients, 1398 were assessable for the QL study.
The submission rate of the QL form was 87% (1213) at baseline
declining to 75% (1044) at month 24. The definition of the sample
is shown in Table 1. The patient characteristics are shown in
Table 2.
Figure 1 depicts the expected short-term effect between
treatments at month 3, with less severe tiredness (P¼0.01) in
patients receiving Tam alone, as compared to those patients with
three initial cycles of CMF. Nausea/vomiting (Po0.01) and
appetite were similarly affected (Po0.01). Also, at 3 months,
physical well being (Po0.01) and mood (Po0.01) showed effects
in favour of Tam alone. Subjective health estimates (SHE) were
similarly affected (P¼0.02), as displayed in Figure 2. In contrast,
patients receiving CMF reported less hot flushes at 3 months
(Po0.01) than those receiving Tam. CMF recipients started
tamoxifen after completing chemotherapy.
The global QL indicators showed effects in favour of Tam alone.
The coping scores indicated a steady improvement over the first 24
months. This adaptation was delayed but not prevented in patients
receiving CMF (Po0.01), as shown in Figure 3. The ratio of the
average change in the coping indicator between baseline and
month 3 in patients with Tam alone vs those with CMF followed by
Table 2 Baseline characteristics of the 1398 patients with available QL
data
Tam CMF-Tam Total
Total eligible cases 701 (100) 697 (100) 1398 (100)
ER-negative 147 (21) 149 (21) 296 (21)
ER-positive 525 (75) 516 (74) 1041 (74)
ER-unknown 29 (4) 32 (5) 61 (4)
Total mastectomy 332 (47) 350 (50) 682 (49)
Breast conservation 369 (53) 347 (50) 716 (51)
With planned RT 322 (87) 313 (90) 635 (89)
Without planned RT 47 (13) 34 (10) 81 (11)
Tumour sizep1.0cm 78 (11) 84 (12) 162 (12)
Tumour size 1.1–2.0cm 336 (48) 335 (48) 671 (48)
Tumour size42.0cm 262 (37) 252 (36) 514 (37)
Tumour size unknown 25 (4) 26 (4) 51 (4)
Tumour grade 1 131 (19) 123 (18) 254 (18)
Tumour grade 2 294 (42) 285 (41) 579 (41)
Tumour grade 3 234 (33) 242 (35) 476 (34)
Tumour grade unknown 42 (6) 47 (7) 89 (6)
Vessel invasion absent 540 (77) 528 (76) 1068 (76)
Vessel invasion present 147 (21) 151 (22) 298 (21)
Vessel invasion not examined 14 (2) 18 (2) 32 (2)
Age (median [range]) 61 [34–78] 60 [44–81] 61 [34–81]
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Figure 1 Median tiredness scores by treatment group over the first 24
months. Higher values indicate less tiredness (i.e. better QL).
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(ratio¼3.37), indicating a clinically meaningful difference. There
was a baseline difference (P¼0.03) with patients assigned to CMF
reporting lower SHE scores. Of these patients, 43% completed the
QL form prior to randomisation (thus up to 57% did so after
knowing treatment assignment), and 95% of all patients with CMF
at day 1 of the first cycle or before (thus 5% did so after
experiencing initial toxicity).
The mean treatment differences in the changes of scores over the
first 3 months are shown in Figure 4. After the completion of
chemotherapy (i.e. month 6 assessment), there were no statistically
significant residual differences between treatment groups for any
of the QL measures.
Similar analyses were performed within the ER-negative and
ER-positive cohorts. Contrary to our hypothesis, there was no
indication for a different treatment effect on QL by ER status
(data not shown).
Quality-adjusted survival
Patients assigned to CMF had improved disease-free survival
(DFS) compared with patients who received Tam alone
([CMFþTam/Tam] RR¼0. 80; 95% CI¼0.64 to 1.00; P¼0.05).
There was also a trend in favour of improved overall survival (OS)
([CMFþTam/Tam] RR¼0.75; 95% CI¼0.55 to 1.02; P¼0.07).
Disease-free survival and OS at 72 months for all 1669 eligible
patients are summarised in Table 3.
The patient derived utilities for the three health states estimated
from SHE scores are shown in Table 4. For Tox, 276 patients with
CMF responded to the SHE question. The patient-derived utility
for this period was 0.89. Of these patients, 66% (N¼183) had a
subjective toxic effect of grade 2 or higher (excluding amenorrhea)
reported during the three cycles. The estimated utility for Tox of
this subgroup was also 0.89.
For TWiST, SHE scores were available for 742 patients. The
estimated utility for this period was 0.91. There was no difference
in utility during TWiST by randomised treatment. For Rel, SHE
scores were available for 37 patients. Those who relapsed after
adjuvant CMF indicated a trend to lower SHE scores (med-
ian¼0.5, range: 0.10–0.99) than those initially treated with Tam
alone (median¼0.62, range: 0.26–1.0). Given the small subgroups,
we used the overall SHE scores (median¼0.54) for QAS
(ur¼0.71).
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Figure 2 Median scores of subjective health (SHE) by treatment group
over the first 24 months. Higher values indicate better health estimates.
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Figure 3 Median scores of coping effort (PACIS) by treatment group
over the first 24 months. Higher values indicate less effort to cope (i.e.
better QL).
QL measures
SHE
Arm movement
Social support
Coping effort
Nauseal/vomiting
Hot flushes
Appetite
Tiredness
Mood
Physical well being
Change in score from baseline to month 3
CMF better Tam alone better
−20 −10 01 0 2 0 3 0
Figure 4 Mean treatment differences over the first 3 months with their
respective 95% confidence intervals (N¼914). Positive values indicate
either an improvement or less deterioration in QL for patients randomised
to receive Tam alone compared with patients randomised to receive CMF
followed by Tam.
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72 months of randomisation are summarised in Table 5. The
calculation of Q-TWiST is illustrated by the weighted combination
of these components using the patient-derived estimates of
ut¼0.89, utwist¼0.91 and ur¼0.71. Based on these utilities, the
average Q-TWiST within the first 6 years for patients receiving
CMF followed by Tam was 62.5 months, 1.1 month longer than
patients receiving Tam alone (P¼0.03).
Patients benefited from adjuvant chemotherapy if their ER-
status was negative, with an average gain in Q-TWiST of 3 months
as compared to those with tamoxifen alone (P¼0.03). Patients
with ER-positive tumours obtained no Q-TWiST benefit from the
chemotherapy .
Figure 5 allows a sensitivity analysis to display the effect on
Q-TWiST of any combination of utilities during Tox and Rel. To
prepare this figure, we standardised the other utilities relative to
utwist For example, a conventional treatment comparison for DFS
makes no deduction for reduced utility during Tox (ut¼utwist¼1).
Based on these assumptions, CMF followed by Tam is obviously
preferred to Tam alone. Taking into account different values for
Tox (uto1;utwist¼1) and including Rel, there is a gain in Q-TWiST
for CMF followed by Tam for most values of ut and ur. This trend
towards an improvement reaches statistical significance for
Table 3 Overall survival (OS)and DFS by treatment at 72 months (N¼1669)
No. of patients No. of events 6-year DFS% (s.e.) P No. dead 6-year OS% (s.e.) P
Overall
Tam 846 166 78 (2) 0.05 94 87 (1) 0.07
CMF-Tam 823 138 83 (1) 73 91 (1)
ER-negative
Tam 190 57 67 (4) 0.003 38 75 (4) 0.01
CMF-Tam 192 33 83 (3) 21 88 (3)
ER-positive
Tam 621 101 81 (2) 0.92 51 90 (2) 0.80
CMF-Tam 596 101 82 (2) 50 92 (1)
DFS¼disease-free survival; s.e.¼standard error.
Table 4 Calculated utility coefficients
Health state N
a SHE TTO¼1 (1 SHE)
1.6
Tox (CMF)
Overall 276 0.76 0.89
ER-negative 59 0.75 0.89
ER-positive 217 0.76 0.90
TWiST
Tam alone 384 0.80 0.91
CMF 358 0.80 0.91
ER-negative overall 161 0.80 0.91
ER-positive overall 578 0.80 0.91
Rel
Tam alone 23 0.62 0.86
CMF 14 0.50 0.66
Total sample 37 0.54 0.71
ER-negative overall 12 0.54 0.71
ER-positive overall 24 0.56 0.73
aSample size reflects those patients who experienced that health state and who
responded to the SHE question at least once during that health state.
SHE¼subjective health estimation; TTO¼time trade-off ; ER¼oestrogen receptor.
Table 5 Components of Q-TWiST
Treatment group
Health state Tam alone (s.e.) CMF-Tam (s.e.) Difference (s.e.) (95% CI) P
Tox
Overall 0 (0) 1.7 (0.1) — — —
ER-negative 0 (0) 1.8 (0.1) — — —
ER-positive 0 (0) 1.7 (0.1) — — —
TWiST
Overall 63.4 (0.7) 64.0 (0.6) — — —
ER-negative 57.7 (1.7) 62.6 (1.4) — — —
ER-positive 65.4 (0.7) 64.2 (0.7) — — —
Rel
Overall 5.1 (0.5) 3.8 (0.4) — — —
ER-negative 7.5 (1.2) 3.3 (0.9) — — —
ER-positive 4.5 (0.6) 4.2 (0.6) — — —
Q-TWiST
Overall 61.4 (0.4) 62.5 (0.3) 1.1 (0.5) (0.1–2.1) 0.03
ER-negative 57.8 (1.1) 60.8 (1.0) 3.0 (1.4) (0.2–5.8) 0.03
ER-positive 62.7 (0.4) 63.0 (0.4) 0.3 (0.5) ( 0.6–1.3) 0.50
Averaged months of Tox, TWiST and Rel accumulated within 72 months of randomisation, with Q-TWiST calculated for patient-derived utility coefficients (N¼1669).
s.e.¼standard error; ER¼oestrogen receptor.
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values of ur as displayed in the upper left portion of the figure. For
low values of ut combined with high values of ur, there is a
nonsignificant benefit for tamoxifen alone as displayed in the
lower right portion of the figure.
Figures 6 and 7 display similar threshold plots for the ER-
negative and ER-positive cohorts, respectively. For patients with
ER-negative tumours, CMF followed by Tam is favoured for all
values of ut and a broad range of ur. For patients with ER-positive
tumours, there was no benefit from the chemotherapy in terms of
Q-TWiST. The trend towards an improvement in Tam alone
reaches statistical significance in a small area defined by very low
values of ut and high values of ur.
Finally, we performed a sensitivity analysis for a range of
proposed a’s used to transform the SHE scale to reflect a TTO
scale. After using an a of 1.4, the utilities for each of the three
health states were similar although slightly reduced. After using an
a value of 1.8, again the utilities were similar for all three health
states although slightly higher. Thus, incorporating utilities using
an a within the range of 1.4–1.8 would not markedly affect the
results obtained from our Q-TWiST analysis (data not shown).
DISCUSSION
The main objective of these analyses was to link QL and QAS in
comparing the randomised treatments. In addition, we investi-
gated whether there was a difference in the magnitude of the
chemotherapy effect according to ER status of the primary tumour
as was found for survival in this trial (International Breast Cancer
Study Group, 2002).
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Figure 5 Threshold utility analysis of the total sample (N¼1669). The
diagonal lines indicate the units of months gained in Q-TWiST for different
utilities for Tox and Rel. The utility for TWiST is defined as utwist¼1 (i.e.
reference state). The solid line labelled 0 is the threshold above which CMF
followed by Tam results in improved Q-TWiST. The area below 0 with
hatch marks represents improved Q-TWiST for Tam alone. The shaded
region (top left) represents utilities (ut and ur) for which the improvement
in Q-TWiST is statistically significant (Pp0.05). S¼significant and NS¼not
significant.
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Figure 6 Threshold utility analysis of the ER-negative cohort (N¼382).
The diagonal lines indicate the units of months gained in Q-TWiST for
different utilities for Tox and Rel. The utilities for TWiST is defined as
utwist¼1 (i.e. reference state). All values of the utilities for Tox and Rel
result in improved Q-TWiST for CMF followed by Tam compared with
Tam alone. The shaded region (top left) represents utilities (ut and ur) for
which the improvement in Q-TWiST is statistically significant (Pp0.05).
S¼significant and NS¼not significant.
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Figure 7 Threshold utility analysis of the ER-positive cohort (N¼1217).
The diagonal lines indicate the units of months gained in Q-TWiST for
different utilities for Tox and Rel. The utilities for TWiST is defined as
utwist¼1 (i.e. reference state). The solid line labelled 0 is the threshold
above which CMF followed by Tam results in improved Q-TWiST. The
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which the improvement in Q-TWiST is statistically significant for Tam alone
(P p 0.05). S¼significant and NS¼not significant.
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lQuality of life
The subjective impact of adjuvant therapy was investigated over
the first 24 months of treatment. At month 3, patients receiving
CMF reported the expected side effects. Better QL in patients with
Tam alone was also indicated by the various global measures of
well being, coping and health status, despite the earlier beginning
of hot flushes for the Tam alone group.
After completing chemotherapy, QL scores rapidly improved as
found in our previous trials (Hu ¨rny et al, 1996b; The International
Breast Cancer Study Group, 2001) and in an adjuvant trial by the
Eastern Cooperative Oncology Group with a more comprehensive
QL questionnaire (Fairclough et al, 1999). Contrary to our
hypothesis, patients’ perception of chemotherapy was not affected
by the ER status of their tumour.
We faced problems with the timing of administration for the
baseline QL assessment. A substantial proportion of patients
completed the QL form after randomisation but before starting
CMF. These patients were presumably aware of their assigned
treatment. The baseline scores may reflect an anticipation of cytotoxic
side effects or perception of worse health status, as described for
indicators of QL and health status and for preference measures (Hu ¨rny
et al,1 9 9 4 ;H u ¨rny et al, 1996b; Jansen et al,2 0 0 1 b ) .T oe l i m i n a t ea n y
differential anticipatory effects on baseline scores in future studies, we
have introduced a completed QL form as an eligibility criterion.
Overall, the improvement in QL over the first 6 months was more
pronounced than the transient impairment by chemotherapy. These
findings confirm those of IBCSG Trials VI and VII (Hu ¨rny et al,
1996b), suggesting that a patient’s psychological adaptation is more
important for her QL than cytotoxic side effects. There were no
residual effects of CMF as assessed by our indicators. Similarly, in a
survey in premenopausal women with node-negative breast cancer
treated with or without adjuvant CMF, there were no long-term
effects of CMF in general and breast cancer-specific QL domains (Joly
et al, 2000). This finding does not exclude long-term sequelae, such as
fatigue (Bower et al, 2000), or impaired sexual (Broeckel et al, 2002)
or cognitive functioning (Phillips and Bernhard, 2003), in subgroups.
Quality-adjusted survival
The Q-TWiST method has hitherto used utilities assigned
arbitrarily (Goldhirsch et al, 1989) or estimated based on patient
reported QL (Fairclough et al, 1999). Although this approach
provides a useful decision aid via a threshold analysis, we wanted
to take into account patients’ own perception of their health status.
We used a global indicator for health status to reflect the patients’
perception across the three distinct health states (Tox, TWiST, Rel)
(Hu ¨rny et al, 1998). This extension of the Q-TWiST model has
provided new information for decision-making. The extent of
impairment during Tox was less severe than the conventional
assumptions. This finding is not related to the timing of the baseline
assessment as we used only the scores at month 3. Our finding is
consistent with those of preference studies showing that a majority
of patients who previously received adjuvant chemotherapy for
breast cancer accept the morbidity of these therapies in turn for a
relatively modest survival gain (Lindley et al, 1998; Ravdin et al,
1998; Jansen et al, 2001a; Simes and Coates, 2001).
The SHE scores during the TWiST health state were less than
‘perfect’ and relatively close to the Tox scores. The fact of having
cancer and late effects of surgical and systemic treatments may have
had an impact on the health estimates (Broeckel et al, 2000; Ganz
et al, 2002). All patients received Tam. Endocrine side effects may
be under-reported (Fellowes et al, 2001), especially vasomotor and
gynaecological symptoms (Day et al, 1999; Fallowfield et al, 2001).
The SHE scores during the Rel state were distinctly worse than
those of Tox and TWiST, although better than the arbitrary values
used in previous analyses. For a majority, the relatively high value may
reflect their readjustment and the beneficial impact of the treatment
for advanced disease (Bernhard et al, 1999). However, there was
substantial variability due to both the small number of patients who
had a recurrence and the limited information available on these cases.
Overall Q-TWiST accumulated within 72 months after randomisa-
tion indicated an advantage of 1 month longer of ‘perfect health’ with
CMF rather than Tam alone. However, in the ER-negative cohort, three
cycles CMF provided 3 months more of Q-TWiST than Tam alone,
w h i l ef o rt h el a r g e rE R - p o s i t i v ec o h o r t ,C M Fp r o v i d e dn ob e n e f i t .
The findings of the QAS analysis thus complement and expand
those of the QL investigation. They provide additional information
for clinical policy and decision-making in postmenopausal
patients with node-negative breast cancer: Taking patients’ view
into account, patients benefited substantially from adjuvant
chemotherapy if their ER status was negative.
These analyses are truncated at 72 months follow-up. Further follow-
up will enhance any advantage of chemotherapy over Tam alone.
In contrast to other studies using global indicators of health status
for QAS analysis (Earle et al, 2000), we specified the frame of
individual reference. Patients were asked to imagine they would have
to live the rest of their life in their current condition and then to rate
their concurrent condition. Although not a true preference measure,
this indicator is suitable for large-scale phase-III trials taking into
account patients’ own evaluation of distinct health states within a given
context (e.g. culture). Our premise was to evaluate estimates based on
actual experience instead of hypothetical scenarios. Experience
of breast cancer (Ashby et al, 1994) and adjuvant chemotherapy
(Lindley et al, 1998; Jansen et al, 2001b) have been shown to be
associated with current preferences. Most often, this type of evaluation
is based on cross-sectional comparisons (Earle et al, 2000). A repeated
formal utility interview is not feasible in an international phase-III trial
and would not imply ap r i o r ia better performance than a rating scale
such as our SHE indicator (Giesler et al, 1999).
The method of insertion of utility values into decision models by
multiplication of utilities and time assumes the independence of
time and values. This assumption has been challenged (Bleichrodt
and Johannesson, 1997; Bala et al, 1999; Stiggelbout et al, 1995;
Bernhard et al, 2001). Preference studies in cancer patients with
repeated assessment reported both reasonably stable (O’Connor
et al, 1987; Llewellyn-Thomas et al, 1993; Jansen et al, 2001b) and
unstable (Llewellyn-Thomas et al, 1992; Jansen et al, 2000) utilities,
suggesting caution in interpreting single point estimates. Variation
in self-report health status across distinct clinical situations is
plausible and argues for a longitudinal evaluation.
Further developments include the relationship between additional
QL domains, such as fatigue (Sadler and Jacobsen, 2001) and
cognitive function (Phillips and Bernhard, 2003), and the SHE-scores
across different health states (Lowy and Bernhard, 2004). Finally, this
concept can be adapted to the palliative setting where there are no
clearly separated health states (Glasziou et al, 1998; Cole et al, 2004).
In summary, patients receiving initial CMF indicated the
expected adverse impact on QL and a delay in adaptation compared
to those assigned Tam alone. The patient estimated utilities for
TWiST indicated less than ‘perfect health’ under Tam. Longitudinal
evaluations of SHE scores provide important information for QAS
(Q-TWiST) analysis and clinical decision-making.
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